Extending these observations, recent work has demonstrated the efficacy of NK‐Exos in neuroblastoma.[279] In MYCN‐amplified neuroblastoma models, NK‐Exos enriched with miR‐186 suppressed tumor proliferation and migration by targeting MYCN, AURKA, and TGF‐β receptors. Here, MYCN is linked to neoplasm.